Historical Genesis and the Evolution of Policy Frameworks
The pharmaceutical industry in Bangladesh stands as a primary archetype of successful import substitution and subsequent export-oriented growth within a developing economy context. The historical trajectory of the sector is defined by a decisive shift from deep-seated dependency on multinational corporations (MNCs) in the post-liberation era to a state of near-total domestic self-sufficiency in the contemporary period.1 During the early 1970s and late 1980s, the market was characterized by a disproportionate concentration of foreign entities, with MNCs controlling approximately 75% to 85% of the pharmaceutical market share, leaving local firms with a marginal presence of 15%.3 The lack of domestic manufacturing capacity necessitated the mass importation of even basic therapeutic agents, leading to significant foreign exchange outflows and precarious public health security.
The catalytic moment for the industry’s transformation arrived with the promulgation of the Drug Ordinance of 1982. This regulatory intervention was revolutionary in its intent to prioritize indigenous manufacturing by restricting the production and importation of non-essential and redundant drugs, thereby creating a structural vacancy for local entrepreneurs to occupy.4 The ordinance mandated that local firms take the lead in producing essential medicines, effectively curbing the dominance of MNCs and providing the protectionist cradle required for early-stage industrial scaling. This policy-driven evolution was further bolstered by the 1988 initiative of Gonoshasthaya Pharmaceuticals, which marked the first domestic effort in Active Pharmaceutical Ingredient (API) synthesis, specifically producing the penicillin antibiotic Amoxicillin ().7
By the early 2000s, the sector had reached a critical mass, transitioning from basic formulation to high-tech manufacturing. The National Drug Policy of 2016 and subsequent investment-friendly industrial policies have since focused on globalizing the sector, leveraging the World Trade Organization (WTO) TRIPS (Trade-Related Aspects of Intellectual Property Rights) waiver granted to Least Developed Countries (LDCs). This waiver, which has been extended to 2033, allows Bangladeshi firms to manufacture generic versions of patented molecules without intellectual property constraints, a unique advantage that has fostered the growth of a robust branded generic market.1
Data sources: 1
Macroeconomic Trajectory and Market Segmentation
The contemporary pharmaceutical market in Bangladesh is valued at approximately USD 3 billion to USD 4 billion, with definitive projections suggesting a surge beyond USD 6 billion by 2025.1 This expansion is underpinned by an average annual growth rate of 12% to 17% over the last decade, far exceeding the global industry average.1 The sector currently contributes between 1.83% and 2.0% to the national Gross Domestic Product (GDP), representing the second-largest tax-paying industrial group and the second-highest contributor to the national exchequer after agriculture.1
The domestic consumption landscape is driven by shifting demographic profiles and rising healthcare expenditures. Individual healthcare spending in Bangladesh increased threefold in the preceding decade, rising from USD 15.8 to USD 41.9 per person, while the count of private healthcare establishments rose from 3,536 in 2000 to nearly 17,000 by 2021.11 This demand is highly concentrated among top-tier domestic players. While there are 213 to 271 registered allopathic manufacturing companies, the top ten firms command approximately 68.49% to 70% of the market share, and the top twenty companies control over 86.33% to 92.2%.1
Market leadership is defined by companies such as Square Pharmaceuticals (holding approximately 16.94% to 18% market share), followed by Incepta, Beximco, Renata, and Opsonin.11 The therapeutic segmentation of the market reveals a heavy reliance on alimentary and metabolism agents, which account for 36.40% of sales, followed by systemic anti-infectives (16.37%) and nervous system drugs (10.44%).16 Large-scale projects are increasingly targeting high-value niche segments, including oncology, which currently meets 4% of domestic demand but is projected to grow as local manufacturing for anti-cancer drugs, hormones, and insulin expands.8
Data sources: 14
Institutional and Regulatory Governance
The regulatory apparatus governing the pharmaceutical sector is anchored by the Ministry of Health and Family Welfare (MOHFW) and executed through the Directorate General of Drug Administration (DGDA).8 The DGDA serves as the primary watchdog, responsible for the oversight of drug manufacturing, importation, quality control, and pricing.18 To align with global benchmarks, the DGDA has implemented a comprehensive Quality Management System (QMS) that mirrors international standards such as ISO 9001 and WHO-GMP.19
Compliance with the World Health Organization’s Good Manufacturing Practice (GMP) guidelines is a statutory requirement under Section 15 of the Drug Ordinance 1982.15 The DGDA has formally adopted a suite of WHO Technical Report Series (TRS) to guide manufacturing inspections, including TRS 902 for national inspectorates, TRS 986 for general GMP, and TRS 957 for active pharmaceutical ingredients.21 For large-scale pharmaceutical projects, obtaining a manufacturing license involves a multi-stage process of document submission, layout approval, physical facility inspection, and gap analysis.18
The institutional framework also includes the Pharmacy Council of Bangladesh, which regulates pharmacy practice and education, and the Bangladesh Association of Pharmaceutical Industries (BAPI), which acts as the lead representative body for the 250+ local drug makers.14 Furthermore, the National Regulatory System has achieved significant international validation, with the National Control Laboratory (NCL) gaining recognition as compliant with WHO-recommended standards for Good Practices for Pharmaceutical Quality Control Laboratories (GPPQCL).25 This prequalification is essential for ensuring that medicines produced in Bangladesh meet the quality thresholds required for procurement by international health organizations and for entry into highly regulated markets.25
Plant Layout, Engineering, and GMP Infrastructure
The design and construction of large-scale pharmaceutical facilities in Bangladesh must adhere to rigid engineering standards to prevent cross-contamination and ensure the safety of therapeutic goods. Central to this is the requirement that pharmaceutical plants be located and designed to suit the specific operations carried out within them.26 The factory buildings must be solid, dust-proof, and designed to exclude rodents and insects, with smooth, crack-free interior surfaces that facilitate disinfection and cleaning.26
Environmental Control and HVAC Systems
Heating, Ventilation, and Air Conditioning (HVAC) systems are categorized as "direct impact" systems by regulatory authorities, as any failure in air quality control can result in immediate batch rejection or product recalls.28 For large-scale manufacturing, HVAC systems must support various cleanroom classifications, typically ranging from ISO 5 to ISO 8.28
Aseptic Areas: High-risk zones such as filling and compounding require ISO 5 (Grade A) environments with terminal HEPA (High-Efficiency Particulate Air) filtration and high air change rates.26
Pressure Differentials: The maintenance of a pressure cascade is vital; positive pressure is utilized to protect sterile areas from external airborne contaminants, while negative pressure may be required in zones handling potent compounds or powders to prevent cross-contamination.26
Conditions: Standard manufacturing zones are generally maintained between 18°C and 25°C, with relative humidity levels between 40% and 60% to ensure the stability of chemical formulations and the comfort of the workforce.26
Technical Utility Requirements
The utility infrastructure for large-scale operations involves specialized Water for Injection (WFI) plants and Pure Steam Generators. According to WHO TRS 992, hold-time studies must be conducted for intermediate products to ensure that environmental conditions do not compromise the microbial load or stability of the drug during the manufacturing cycle.21 Plumbing must be designed to avoid leaking joints or stagnant points, and electrical systems must be integrated to support 24-hour uninterrupted operation, which is critical for continuous processes like tablet coating or chemical synthesis.7
Data sources: 26
The API Ecosystem and Backward Linkage Strategy
Despite the maturity of its formulation sector, Bangladesh remains heavily dependent on the importation of raw materials. Over 90% to 95% of Active Pharmaceutical Ingredients and laboratory reagents are imported annually, primarily from China and India, at a cost exceeding USD 1.2 billion to USD 1.3 billion.8 This dependency represents a significant vulnerability, particularly regarding price volatility and supply chain disruptions. In response, the government has prioritized the development of a self-reliant API ecosystem as a critical "thrust sector" for industrial expansion.4
The API Industrial Park at Munshiganj
The flagship initiative for backward linkage is the 200-acre Active Pharmaceutical Ingredient Industrial Park in Gazaria, Munshiganj, established by the Bangladesh Small and Cottage Industries Corporation (BSCIC).7 The park is designed to host 42 plots allocated to 27 leading pharmaceutical companies, including Square, Beximco, Incepta, and Acme.7 Once fully operational, the park is expected to provide employment for 25,000 people and save approximately 70% of the import costs of raw materials by achieving domestic economies of scale.9
Technical facilities at the API Park include a Common Effluent Treatment Plant (CETP) and a dedicated waste dumping yard to ensure that the chemical synthesis processes are environmentally sustainable.9 However, as of early 2025, implementation has faced delays. While some companies like Healthcare Chemicals and Axis Pharmaceuticals have established operational plants, the land for 23 other companies remains largely underutilized due to acute utility shortages, including the lack of high-pressure gas connections and voltage fluctuations in the power supply.7
API Policy and Fiscal Incentives
The National API and Laboratory Reagents Production and Export Policy of 2018 provides a comprehensive framework of incentives to encourage domestic synthesis. Producers manufacturing at least five molecules annually are eligible for a 100% tax holiday, while those producing at least three molecules receive a 75% tax holiday.1 Furthermore, the policy offers a 20% cash incentive for producers who achieve a minimum 20% value addition.9 These fiscal measures are designed to reduce the cost advantage currently held by imported APIs and to attract foreign direct investment into high-tech chemical manufacturing.
Data sources: 1
International Trade, Exports, and Regulatory Approvals
The transformation of the pharmaceutical industry from an import-substitution model to an export-driven powerhouse is one of Bangladesh's most notable industrial success stories. Pharmaceutical products are currently exported to over 150 destinations, including highly regulated markets such as the USA, UK, EU, Canada, and Australia.2 In the first ten months of the 2024–25 fiscal year, pharmaceutical exports rose by 3.46% year-on-year, reaching USD 177.42 million, with some estimates suggesting a year-end figure of USD 213 million.8
Global Competitive Positioning
The industry enjoys a significant cost advantage, with production costs estimated to be 10% to 15% lower than in neighboring India and China.1 This is attributed to competitive labor rates—with monthly labor costs as low as USD 68.99—and favorable trade policies.8 Leading Bangladeshi companies have achieved certifications from the world's most stringent regulatory bodies, including the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Australian Therapeutic Goods Administration (TGA).2
For instance, Beximco Pharmaceuticals has been a pioneer in penetrating the US market, with its facility meeting 90% of certain medication supplies to the United States.11 Incepta and Beacon have also made significant strides in exporting specialized treatments, including oncology medications and antivirals such as Remdesivir and Favipiravir during the COVID-19 pandemic.1 To support this outward expansion, the government provides a 6% export subsidy on pharmaceutical products and a 5% subsidy on exported Active Pharmaceutical Ingredients.8
Export Destination Analysis
Sri Lanka remains the largest destination for Bangladeshi medicaments, accounting for approximately USD 27.9 million in 2024, followed by the United States (USD 21.3 million) and the Philippines (USD 18.6 million).33 The industry is also seeing rapid growth in emerging markets such as Chile, Uzbekistan, and Kenya.2 This market diversification is crucial for reducing reliance on any single regional economy and for building the reputation of "Made in Bangladesh" pharmaceuticals as high-quality, affordable alternatives in the global generic market.
Data sources: 33
Intellectual Property and Post-LDC Transition
The primary strategic challenge facing the large-scale pharmaceutical sector in Bangladesh is the impending graduation from Least Developed Country (LDC) status, scheduled for November 2026.35 As an LDC, Bangladesh has been the only nation with a mature pharmaceutical sector to benefit from the WTO TRIPS waiver, which provides the unique ability to reverse-engineer and manufacture patented drugs without the associated licensing costs.2
The TRIPS Cliff and Patent Compliance
Graduation in 2026 will subject the industry to a more robust intellectual property regime. While the WTO has extended the specific transition period for pharmaceutical patents until 2033 for LDCs, the transition period for other TRIPS provisions will end sooner.1 Post-graduation, local firms may face significant obstacles in manufacturing new generic drugs, as they will be required to pay royalties and licensing fees to global patent holders.36
Furthermore, graduation entails the loss of Duty-Free Quota-Free (DFQF) access to major markets. The European Union’s "Everything But Arms" (EBA) scheme will be phased out, necessitating an average tariff payment of 10% to export products to the EU, which currently represents a major growth destination.35 The cumulative effect of increased patent costs and higher tariffs could potentially lead to a 5.5% to 7.5% decline in export revenue if strategic adjustments are not implemented.24
Technological Readiness and Legal Adaptation
In anticipation of this shift, the government enacted the Patent Act of 2023, which modernizes patentability criteria and defines clearer procedures for patent examination and divisional applications.6 The act aim to balance the protection of innovation with the necessity of maintaining access to affordable medicines. Simultaneously, the industry is shifting its focus toward "off-patent" generics—where global patents have expired—and biosimilars, which require sophisticated biotechnological capabilities but are less susceptible to simple patent litigation.8
Large-scale players are increasingly investing in Research and Development (R&D) and Bioequivalence (BE) study centers to prove that their generics are therapeutically identical to the originator brands.17 This technological readiness is seen as the "second wave" of industrial evolution, moving beyond simple formulation assembly into advanced innovation and complex chemical synthesis.37
Public Health Integration and Pricing Policies
A fundamental component of the large-scale pharmaceutical sector is its deep integration with the national public health agenda. In early 2025, the government introduced the National Medicine Pricing Policy 2025, a landmark regulatory shift aimed at ensuring the affordability of life-saving drugs.39
The 25% Essential Medicines Mandate
Under the new policy, the National Essential Medicines List was expanded from 135 to 295 drugs, covering treatments for nearly 80% of common diseases.39 Crucially, the government has mandated that pharmaceutical companies must ensure that at least 25% of their annual sales are derived from these essential drugs.39 This policy reflects a shift toward a more regulated market; companies that fail to meet this threshold will be barred from seeking approval for new generic formulations.39
Pricing for these essential medicines is now determined using a "cost-plus benchmarking" method. The DGDA sets the Maximum Retail Price (MRP) based on the cost of raw materials (APIs and excipients), primary packaging, and class-based markups, while excluding VAT and secondary/tertiary packaging costs to prevent price escalation.39 For non-essential drugs, an "Internal Reference Pricing" (IRP) system is utilized, where the median market price of existing brands serves as the benchmark for new approvals.39
Data sources: 39
The industry's response to these mandates has been nuanced. While public health advocates welcome the move toward affordability, industry leaders argue that the 25% mandatory supply requirement is detached from market realities and could lead to financial losses for smaller manufacturers who lack the economies of scale to produce essential drugs profitably under rigid price caps.39
Investment Environment and Project Feasibility
Bangladesh offers a highly liberalized environment for foreign direct investment (FDI) in the pharmaceutical sector. The Bangladesh Investment Development Authority (BIDA) is the principal agency for promoting and approving private industrial projects.41 Pharmaceutical ventures benefit from 100% foreign ownership, unrestricted exit policies, and 100% profit repatriation.1
Investment Requirements and OSS
For a large-scale pharmaceutical project (exceeding an investment of USD 1.25 million), the investor must submit a project profile to BIDA along with registration from the Registrar of Joint Stock Companies and Firms (RJSC&F) and a No Objection Certificate (NOC) from the Ministry of Health.41 The BIDA One-Stop Service (OSS) Act of 2018 has streamlined these procedures, integrating the services of multiple government agencies, including the Department of Environment and the Fire Service and Civil Defence, into a single digital platform.41
Fiscal and Non-Fiscal Incentives
Investment incentives are substantial. Pharmaceutical and API companies established in designated Economic Zones (EZs) or through BIDA registration enjoy tax holidays ranging from 5 to 10 years.1 They also receive duty-free import facilities for capital machinery and spare parts.43 For export-oriented industries, back-to-back letter of credit (L/C) facilities and bonded warehouse licenses are available, allowing for the duty-free importation of raw materials intended for the global market.9
Furthermore, the banking sector’s exposure to the pharmaceutical industry is characterized by high reliability. In 2023, the pharmaceutical industry accounted for only 1.32% of the total outstanding bank portfolio but had the lowest non-performing loan (NPL) ratio of just 2.87% among all industrial sectors, highlighting the financial stability and bankability of large-scale drug manufacturing projects.14
Data sources: 23
Specialized Workforce and Innovation Readiness
The pharmaceutical industry is a major white-collar employer in Bangladesh, providing high-value jobs to thousands of pharmacists, chemists, microbiologists, and engineers.8 The "Triple Helix" model—a collaboration between government policy, industrial investment, and academic research—has been central to the sector’s manufacturing success.10 However, the move toward a post-TRIPS, innovation-driven model reveals significant human resource gaps.
The Skill Gap in R&D
Research from BRAC University and the Geneva Graduate Institute indicates that while the industry is proficient in reverse engineering, there is a marked absence of expertise in "New Chemical Entity" (NCE) development and advanced biotechnological processes.17 High-end roles in synthesis chemistry, clinical trial management, and gene therapy require specialized training that current domestic university curricula are only beginning to address.24
The industry currently faces a critical demand for:
Synthesis Chemists: To develop the chemical pathways for API production.24
Biotechnologists: To manage cell line development and fermentation for biologics and vaccines.17
Regulatory Affairs Specialists: To navigate the intellectual property laws and patent filings in international markets.46
Clinical Research Associates: To oversee the bioequivalence and bioavailability studies required for global generic approvals.17
Industry-Academia Collaboration
To bridge these gaps, some leading companies have established in-house training centers and initiated collaborations with international universities in Europe, Australia, and India.17 The government’s National Industrial Policy 2023 emphasizes the necessity of embracing technological advantages and increasing R&D subsidies to incentivize firms to move from being "producers of known drugs" to "innovators of new molecules".4
Future Outlook and Strategic Synthesis
The large-scale pharmaceutical industry in Bangladesh is at a critical juncture. Having achieved 98% self-sufficiency and established a global export footprint, the sector must now transition into a high-value, TRIPS-compliant entity. The focus is shifting from simple oral solid dosages (tablets and capsules) toward specialized formulations, including oncology, hormones, insulin, and biosimilars.8
The successful operationalization of the API Industrial Park and the consistent supply of utilities—gas and electricity—will be the single most important factor in maintaining the industry’s cost-competitiveness after LDC graduation.7 Simultaneously, the expansion into the medical device (MedTech) sector represents a USD 800 million opportunity, where domestic manufacturing currently meets only 5-7% of demand.10
By leveraging its existing manufacturing base, a young and trainable workforce, and strong government policy support, Bangladesh is well-positioned to become a regional hub for affordable healthcare solutions. However, the sustainable growth of the sector will depend on its ability to internalize R&D, secure intellectual property rights, and adhere to increasingly stringent global environmental and quality standards. For the large-scale investor, the Bangladeshi pharmaceutical sector offers a high-growth, low-risk opportunity within one of Asia’s most resilient and technologically progressive industrial landscapes.
Works cited
Pharma & API - BIDA, accessed March 3, 2026, https://boi.gov.bd/pharma-api
Export Dynamics of the Pharmaceutical Industry in Bangladesh - ResearchGate, accessed March 3, 2026, https://www.researchgate.net/publication/397885471_Export_Dynamics_of_the_Pharmaceutical_Industry_in_Bangladesh
POTENTIAL AND POSSIBILITIES Joint Secretary Razia Begum, ndc Introduction The pharmaceutical industry, accessed March 3, 2026, https://ndcjournal.ndc.gov.bd/ndcj/index.php/ndcj/article/download/43/39
An AZ Pharmaceutical Industry: Bangladesh Perspective - Asian Journal of Research in Pharmaceutical Sciences, accessed March 3, 2026, https://ajpsonline.com/HTMLPaper.aspx?Journal=Asian%20Journal%20of%20Research%20in%20Pharmaceutical%20Sciences;PID=2019-9-1-4
Pharmaceutical Sector of Bangladesh: Prospects and Challenges - CORE, accessed March 3, 2026, https://files01.core.ac.uk/download/pdf/61804208.pdf
A Project of World Intellectual Property Organization (WIPO), accessed March 3, 2026, https://objectstorage.ap-dcc-gazipur-1.oraclecloud15.com/n/axvjbnqprylg/b/V2Ministry/o/office-dpdt/2024/12/f5c028294baa4386add0bb8be146e018.pdf
Drug-manufacturing raw material industry fails to take off | Prothom Alo, accessed March 3, 2026, https://en.prothomalo.com/bangladesh/l4mu61zp7o
Bangladesh Pharmaceutical & API Industry, accessed March 3, 2026, https://investbangladesh.gov.bd/investment-sector/pharma-api
Active Pharmaceutical Ingredient (API) Manufacturing: The Next Growth Driver of The Bangladesh Pharmaceutical Industry - LightCastle Partners, accessed March 3, 2026, https://lightcastlepartners.com/insights/2021/08/active-pharmaceutical-ingredient-api-manufacturing-the-next-growth-driver-of-the-bangladesh-pharmaceutical-industry/
Strengthening Medical Technology Innovation Ecosystems to ..., accessed March 3, 2026, https://www.wipo.int/web-publications/strengthening-medical-technology-innovation-ecosystems-to-address-non-communicable-diseases-in-least-developed-countries/en/bangladesh-case-study.html
Pharmaceuticals - Invest Bangladesh, accessed March 3, 2026, https://investbangladesh.co/pharmaceuticals/
Economic Profile - Consulate General of the People's Republic of Bangladesh, Dubai, accessed March 3, 2026, https://bcgdubai.gov.bd/economic-profile/
Pharmaceutical Industry of Bangladesh: Progress and Prospects - Academia.edu, accessed March 3, 2026, https://www.academia.edu/33075648/Pharmaceutical_Industry_of_Bangladesh_Progress_and_Prospects
Pharmaceutical Industry in Bangladesh: Upholding Global Standards, Expanding Global Reach - IDLC Home, accessed March 3, 2026, https://mbr.idlc.com/industry-insight/pharmaceutical-industry-in-bangladesh-upholding-global-standards-expanding-global-reach
Quality Control and Inventory Management Practices at Pharmaceuticals Industries in Bangladesh - UAP, accessed March 3, 2026, https://www.uap-bd.edu/recent-paper-publication/inventory_tarannum.pdf
Overall Scenario of Bangladesh Pharma Market Problems and Prospects, accessed March 3, 2026, https://cdn6.f-cdn.com/files/download/112845318/PHT%20604-converted.pdf
Pharmaceutical R&D in Bangladesh: Ground Realities and Prospects - Geneva Graduate Institute, accessed March 3, 2026, https://www.graduateinstitute.ch/sites/internet/files/2023-07/BRAC_University_teaching_materials_OSUN_Research_Collaboration_JULY2023.pdf
GMP Compliance and Inspection Standards in Bangladesh – pharma gxp, accessed March 3, 2026, https://www.pharmaregulatory.in/gmp-compliance-and-inspection-standards-in-bangladesh-pharma-gxp/
Untitled, accessed March 3, 2026, https://objectstorage.ap-dcc-gazipur-1.oraclecloud15.com/n/axvjbnqprylg/b/V2Ministry/o/office-dgda/2024/12/819dcbe48ce04dfd9ea55f2d949fb8ae.pdf
GMP (Good Manufacturing Practices) Compliance Certification in Bangladesh, accessed March 3, 2026, https://www.b-advancy.com.bd/post/gmp-good-manufacturing-practices-compliance-certification-in-bangladesh
DGDA Office Order of Adoption of WHO Guideline(1), accessed March 3, 2026, https://objectstorage.ap-dcc-gazipur-1.oraclecloud15.com/n/axvjbnqprylg/b/V2Ministry/o/office-dgda/2024/12/018788ef5b224481a3653af7e2b88229.pdf
Good Manufacturing Practices (GMP) Certification for Pharmaceuticals in Bangladesh, accessed March 3, 2026, https://hmsuniversal.com/gmp-certification-for-pharmaceuticals-in-bangladesh/
Approval, Format & Registration of Pharmaceutical Product in Bangladesh | PDF - Scribd, accessed March 3, 2026, https://www.scribd.com/document/945614959/Approval-Format-Registration-of-Pharmaceutical-Product-in-Bangladesh
(PDF) Problem and Prospect of Pharmaceuticals Industry of Bangladesh amid LDC Graduation - ResearchGate, accessed March 3, 2026, https://www.researchgate.net/publication/376851259_Problem_and_Prospect_of_Pharmaceuticals_Industry_of_Bangladesh_amid_LDC_Graduation
Bangladesh achieves international recognition in quality testing for medicines, accessed March 3, 2026, https://www.who.int/bangladesh/news/detail/13-04-2020-bangladesh-achieves-international-recognition-in-quality-testing-for-medicines
REGULATORY REQUIREMENTS FOR PHARMACEUTICAL PLANTS - BSP Books, accessed March 3, 2026, https://www.bspublications.net/downloads/052e20f8447cfa_pharmaceutical%20facilities_chapter-1.pdf
Design & Layout of a Pharmaceutical Plant - ResearchGate, accessed March 3, 2026, https://www.researchgate.net/publication/387896342_Design_Layout_of_a_Pharmaceutical_Plant
HVAC System Design Requirements for Pharma Manufacturing, accessed March 3, 2026, https://jdpharmaconsultants.co.in/hvac-system-design-requirements-for-pharma-manufacturing/
Regulatory Requirements for HVAC Design (FDA, WHO, EMA) - Pharma Validation, accessed March 3, 2026, https://www.pharmavalidation.in/regulatory-requirements-for-hvac-design-fda-who-ema/
Brief Outline, accessed March 3, 2026, http://www.bapi-bd.com/api-park/brief-outline.html
Newsroom | Healthcare Chemical Ltd., accessed March 3, 2026, https://hclapibd.com/news.html
Despite generous incentives, foreign investors sidestep Bangladesh's industrial enclaves, accessed March 3, 2026, https://asianews.network/despite-generous-incentives-foreign-investors-sidestep-bangladeshs-industrial-enclaves/
Pharmaceutical products in Bangladesh Trade | The Observatory of Economic Complexity, accessed March 3, 2026, https://oec.world/en/profile/bilateral-product/pharmaceutical-products/reporter/bgd
Export Dynamics of the Pharmaceutical Industry in Bangladesh - ResearchGate, accessed March 3, 2026, https://www.researchgate.net/publication/397730160_Export_Dynamics_of_the_Pharmaceutical_Industry_in_Bangladesh
Export Policy 2024-2027 Ministry of Commerce - The Bangladesh Trade Portal, accessed March 3, 2026, https://www.bangladeshtradeportal.gov.bd/kcfinder/upload/files/Legal_1756180440.pdf
Untitled - BIDA, accessed March 3, 2026, https://bida.portal.gov.bd/storage/app/uploads/public/679/713/46c/67971346c29d9782914741.pdf
Technological Readiness of Bangladeshs Pharmaceuticals Industry - Scribd, accessed March 3, 2026, https://www.scribd.com/document/969752366/Technological-Readiness-of-Bangladeshs-Pharmaceuticals-Industry
TECHNOLOGICAL READINESS OF BANGLADESH'S PHARMACEUTICALS INDUSTRY Preparing for LDC Graduation - Centre for Policy Dialogue (CPD), accessed March 3, 2026, https://cpd.org.bd/resources/2025/01/Technological-Readiness-of-Bangladeshs-Pharmaceuticals-Industry.pdf
Pharma must sell 25% essential drugs - Justnewsbd, accessed March 3, 2026, https://www.justnewsbd.com/en/health/news/28430
Pharma must sell 25% essential drugs for new medicine approval, govt mandates, accessed March 3, 2026, https://www.tbsnews.net/economy/industry/pharma-must-sell-25-essential-drugs-new-medicine-approval-govt-mandates-1336141
2018 Investment Climate Statements: Bangladesh - U.S. Department of State, accessed March 3, 2026, https://www.state.gov/reports/2018-investment-climate-statements/bangladesh
2017 Investment Climate Statements: Bangladesh - U.S. Department of State, accessed March 3, 2026, https://www.state.gov/reports/2017-investment-climate-statements/bangladesh/
Investor's Corner | Project Profile, accessed March 3, 2026, https://projectsprofile.com/pages/investor_corner.html
Setting up a Factory in Bangladesh: Institutional, Operational and Legal Requirements in RMG, Leather, Food processing and Pharmaceutical Sectors - CPD, accessed March 3, 2026, https://cpd.org.bd/resources/2022/09/Setting-up-a-Factory-in-Bangladesh-Institutional-Operational-and-Legal-Requirements.pdf
BIDA Resources – Investment Publications & Reports Bangladesh, accessed March 3, 2026, https://www.bida.gov.bd/resources
Pharmaceuticals Research and Development (R&D) in Bangladesh ..., accessed March 3, 2026, https://repository.graduateinstitute.ch/record/301830/files/267ab2_c72376d75d19408d8e923f0ce56b61ec.pdf
(PDF) Strengthening Bangladesh's Pharmaceutical Industry: A Policy, Market and Sustainability Perspective - ResearchGate, accessed March 3, 2026, https://www.researchgate.net/publication/392910494_Strengthening_Bangladesh's_Pharmaceutical_Industry_A_Policy_Market_and_Sustainability_Perspective
Healthcare & medical Devices Sector Profile - BIDA, accessed March 3, 2026, https://www.boi.gov.bd/storage/app/uploads/public/625/65a/bd9/62565abd9867f595095196.pdf